Andrew Liu
Concepts (397)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 85 | 2022 | 2029 | 7.800 |
Why?
| Hypersensitivity | 16 | 2023 | 252 | 3.430 |
Why?
| Urban Population | 17 | 2022 | 397 | 3.260 |
Why?
| Anti-Asthmatic Agents | 15 | 2020 | 349 | 1.720 |
Why?
| Environmental Exposure | 8 | 2018 | 372 | 1.390 |
Why?
| Allergens | 17 | 2022 | 413 | 1.100 |
Why?
| Severity of Illness Index | 15 | 2021 | 2540 | 1.070 |
Why?
| Child | 71 | 2022 | 18422 | 1.070 |
Why?
| Virus Diseases | 4 | 2022 | 195 | 1.050 |
Why?
| Nasal Mucosa | 6 | 2019 | 93 | 1.030 |
Why?
| Immunoglobulin E | 21 | 2020 | 314 | 0.900 |
Why?
| Endotoxins | 4 | 2013 | 211 | 0.890 |
Why?
| Rhinitis | 5 | 2018 | 128 | 0.870 |
Why?
| Poverty | 7 | 2016 | 442 | 0.850 |
Why?
| Omalizumab | 9 | 2020 | 45 | 0.830 |
Why?
| Phenotype | 7 | 2018 | 2797 | 0.810 |
Why?
| Oscillometry | 3 | 2021 | 33 | 0.800 |
Why?
| Airway Resistance | 2 | 2020 | 29 | 0.760 |
Why?
| Child, Preschool | 33 | 2021 | 9118 | 0.710 |
Why?
| Biological Products | 1 | 2023 | 166 | 0.690 |
Why?
| Hygiene | 4 | 2015 | 27 | 0.680 |
Why?
| Respiratory Function Tests | 8 | 2015 | 522 | 0.660 |
Why?
| Humans | 107 | 2023 | 114709 | 0.660 |
Why?
| Food Hypersensitivity | 3 | 2014 | 251 | 0.630 |
Why?
| Microbiota | 4 | 2022 | 647 | 0.600 |
Why?
| Respiratory Syncytial Virus, Human | 1 | 2018 | 60 | 0.580 |
Why?
| Air Pollution, Indoor | 2 | 2021 | 108 | 0.570 |
Why?
| Adolescent | 40 | 2022 | 17854 | 0.570 |
Why?
| Hygiene Hypothesis | 1 | 2015 | 1 | 0.510 |
Why?
| Respiratory Sounds | 8 | 2022 | 110 | 0.500 |
Why?
| Biological Therapy | 1 | 2015 | 26 | 0.500 |
Why?
| Prevalence | 10 | 2018 | 2251 | 0.480 |
Why?
| Rhinovirus | 6 | 2023 | 40 | 0.460 |
Why?
| Dust | 5 | 2021 | 84 | 0.450 |
Why?
| Adrenal Cortex Hormones | 7 | 2018 | 497 | 0.450 |
Why?
| Male | 60 | 2022 | 55667 | 0.450 |
Why?
| Nitrogen Dioxide | 1 | 2013 | 20 | 0.440 |
Why?
| Disease Progression | 10 | 2021 | 2381 | 0.440 |
Why?
| Female | 61 | 2022 | 59571 | 0.430 |
Why?
| Inhalation Exposure | 1 | 2013 | 97 | 0.420 |
Why?
| Cockroaches | 5 | 2021 | 21 | 0.420 |
Why?
| Models, Theoretical | 1 | 2016 | 515 | 0.410 |
Why?
| Egg Hypersensitivity | 4 | 2016 | 45 | 0.410 |
Why?
| Leukocytes, Mononuclear | 8 | 2021 | 493 | 0.410 |
Why?
| Peanut Hypersensitivity | 5 | 2015 | 197 | 0.410 |
Why?
| Epigenesis, Genetic | 6 | 2018 | 521 | 0.400 |
Why?
| Desensitization, Immunologic | 4 | 2016 | 117 | 0.400 |
Why?
| Nicotine | 1 | 2013 | 265 | 0.370 |
Why?
| Bronchodilator Agents | 6 | 2021 | 239 | 0.370 |
Why?
| Spirometry | 6 | 2021 | 224 | 0.370 |
Why?
| Risk Factors | 15 | 2022 | 8634 | 0.360 |
Why?
| Air Pollutants | 1 | 2013 | 242 | 0.350 |
Why?
| Stress, Psychological | 1 | 2018 | 944 | 0.350 |
Why?
| Hypersensitivity, Immediate | 3 | 2012 | 46 | 0.330 |
Why?
| Primary Health Care | 3 | 2021 | 1514 | 0.330 |
Why?
| Infant | 18 | 2021 | 7968 | 0.330 |
Why?
| Arachis | 5 | 2015 | 146 | 0.320 |
Why?
| Receptors, Pattern Recognition | 1 | 2008 | 9 | 0.320 |
Why?
| Disease Management | 4 | 2016 | 560 | 0.310 |
Why?
| Bacterial Infections | 2 | 2008 | 218 | 0.310 |
Why?
| Maxillary Sinus | 2 | 2009 | 11 | 0.310 |
Why?
| Urban Health | 4 | 2013 | 73 | 0.290 |
Why?
| Precision Medicine | 2 | 2021 | 337 | 0.290 |
Why?
| DNA Methylation | 5 | 2018 | 496 | 0.290 |
Why?
| Environmental Microbiology | 2 | 2007 | 43 | 0.280 |
Why?
| Biomarkers | 6 | 2022 | 3408 | 0.280 |
Why?
| Practice Guidelines as Topic | 7 | 2018 | 1394 | 0.270 |
Why?
| Sinusitis | 1 | 2009 | 174 | 0.270 |
Why?
| Fluticasone | 6 | 2018 | 87 | 0.260 |
Why?
| Immune System | 1 | 2007 | 172 | 0.260 |
Why?
| Transcriptome | 4 | 2022 | 726 | 0.260 |
Why?
| Antibodies, Anti-Idiotypic | 3 | 2013 | 53 | 0.260 |
Why?
| Dermatitis, Atopic | 5 | 2014 | 307 | 0.260 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 1264 | 0.250 |
Why?
| Baltimore | 2 | 2016 | 43 | 0.250 |
Why?
| Prospective Studies | 7 | 2022 | 6220 | 0.240 |
Why?
| Adrenergic beta-Agonists | 2 | 2009 | 126 | 0.240 |
Why?
| United States | 12 | 2022 | 12184 | 0.230 |
Why?
| Respiratory Tract Infections | 2 | 2019 | 319 | 0.230 |
Why?
| Maxillary Sinusitis | 1 | 2004 | 7 | 0.230 |
Why?
| Quality of Life | 2 | 2021 | 2353 | 0.220 |
Why?
| Host-Pathogen Interactions | 2 | 2017 | 295 | 0.220 |
Why?
| Maternal Exposure | 2 | 2018 | 138 | 0.210 |
Why?
| Cities | 2 | 2018 | 80 | 0.210 |
Why?
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 663 | 0.210 |
Why?
| Immunity, Innate | 1 | 2008 | 720 | 0.210 |
Why?
| Picornaviridae Infections | 1 | 2023 | 29 | 0.210 |
Why?
| Eosinophils | 3 | 2019 | 278 | 0.210 |
Why?
| Skin Tests | 7 | 2014 | 116 | 0.210 |
Why?
| Biological Factors | 1 | 2023 | 35 | 0.210 |
Why?
| Treatment Outcome | 13 | 2017 | 9089 | 0.200 |
Why?
| Self Care | 1 | 2005 | 349 | 0.200 |
Why?
| Pediatrics | 1 | 2010 | 981 | 0.200 |
Why?
| Pulmonary Eosinophilia | 1 | 2022 | 25 | 0.200 |
Why?
| Rhinitis, Allergic, Perennial | 2 | 2016 | 23 | 0.200 |
Why?
| Pulmonary Surfactants | 1 | 2023 | 99 | 0.200 |
Why?
| DNA, Bacterial | 1 | 2003 | 312 | 0.200 |
Why?
| Forced Expiratory Volume | 5 | 2017 | 475 | 0.200 |
Why?
| Surveys and Questionnaires | 4 | 2018 | 4624 | 0.190 |
Why?
| Administration, Inhalation | 6 | 2016 | 641 | 0.190 |
Why?
| Double-Blind Method | 10 | 2016 | 1660 | 0.190 |
Why?
| Gene Expression Profiling | 4 | 2017 | 1518 | 0.190 |
Why?
| Respiratory Syncytial Virus Infections | 2 | 2018 | 97 | 0.190 |
Why?
| CpG Islands | 2 | 2018 | 118 | 0.190 |
Why?
| Early Growth Response Protein 1 | 1 | 2021 | 24 | 0.190 |
Why?
| Milk Hypersensitivity | 2 | 2012 | 22 | 0.190 |
Why?
| Immune Tolerance | 2 | 2014 | 323 | 0.190 |
Why?
| Mucin 5AC | 1 | 2021 | 48 | 0.180 |
Why?
| Housing | 4 | 2021 | 114 | 0.180 |
Why?
| Quantitative Trait Loci | 3 | 2021 | 305 | 0.180 |
Why?
| Tobacco Smoke Pollution | 3 | 2016 | 217 | 0.180 |
Why?
| Cross-Sectional Studies | 7 | 2020 | 4411 | 0.180 |
Why?
| Emergency Service, Hospital | 3 | 2021 | 1820 | 0.180 |
Why?
| Adult | 20 | 2022 | 30561 | 0.180 |
Why?
| Enterovirus Infections | 1 | 2023 | 160 | 0.180 |
Why?
| Anti-Allergic Agents | 2 | 2018 | 41 | 0.170 |
Why?
| Intellectual Disability | 1 | 2021 | 128 | 0.170 |
Why?
| Nitric Oxide | 4 | 2015 | 823 | 0.170 |
Why?
| Gene Expression Regulation | 6 | 2021 | 2320 | 0.170 |
Why?
| Bronchial Hyperreactivity | 3 | 2012 | 95 | 0.170 |
Why?
| Autoimmune Diseases | 1 | 2003 | 382 | 0.170 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2021 | 1214 | 0.170 |
Why?
| Interleukin-5 Receptor alpha Subunit | 1 | 2018 | 4 | 0.160 |
Why?
| ERG1 Potassium Channel | 1 | 2018 | 4 | 0.160 |
Why?
| Androstadienes | 3 | 2009 | 97 | 0.160 |
Why?
| Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.160 |
Why?
| Genotype | 2 | 2021 | 1760 | 0.160 |
Why?
| Respiratory System | 1 | 2019 | 137 | 0.150 |
Why?
| Nutrition Surveys | 4 | 2014 | 224 | 0.150 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2018 | 56 | 0.150 |
Why?
| Eczema | 2 | 2010 | 81 | 0.140 |
Why?
| Interleukin-6 | 2 | 2020 | 676 | 0.140 |
Why?
| Acute Disease | 1 | 2020 | 911 | 0.140 |
Why?
| Age of Onset | 2 | 2016 | 446 | 0.140 |
Why?
| Seasons | 5 | 2022 | 442 | 0.140 |
Why?
| Feasibility Studies | 1 | 2020 | 737 | 0.140 |
Why?
| Gene Regulatory Networks | 1 | 2019 | 228 | 0.140 |
Why?
| Lipopolysaccharides | 3 | 2008 | 823 | 0.140 |
Why?
| Age Factors | 4 | 2006 | 2894 | 0.140 |
Why?
| Follow-Up Studies | 6 | 2018 | 4411 | 0.140 |
Why?
| RNA Virus Infections | 1 | 2017 | 11 | 0.140 |
Why?
| Guideline Adherence | 1 | 2021 | 490 | 0.140 |
Why?
| RNA, Ribosomal, 16S | 1 | 2019 | 485 | 0.140 |
Why?
| Fluticasone-Salmeterol Drug Combination | 1 | 2016 | 12 | 0.140 |
Why?
| RNA Viruses | 1 | 2017 | 28 | 0.140 |
Why?
| Epidemiologic Studies | 1 | 2016 | 57 | 0.130 |
Why?
| Basophils | 3 | 2015 | 64 | 0.130 |
Why?
| Down Syndrome | 1 | 2021 | 335 | 0.130 |
Why?
| Lung | 3 | 2023 | 3561 | 0.130 |
Why?
| Antiviral Agents | 2 | 2023 | 645 | 0.130 |
Why?
| Plasma Cells | 2 | 2009 | 56 | 0.130 |
Why?
| Medical History Taking | 1 | 2016 | 114 | 0.130 |
Why?
| Immunization | 2 | 2016 | 397 | 0.130 |
Why?
| Air Pollution | 1 | 2018 | 169 | 0.130 |
Why?
| Longitudinal Studies | 3 | 2019 | 2387 | 0.130 |
Why?
| Socioeconomic Factors | 3 | 2016 | 1079 | 0.130 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2021 | 1880 | 0.130 |
Why?
| Immune System Diseases | 1 | 2015 | 32 | 0.130 |
Why?
| Young Adult | 10 | 2018 | 10471 | 0.130 |
Why?
| Genome-Wide Association Study | 3 | 2018 | 1177 | 0.130 |
Why?
| Sublingual Immunotherapy | 1 | 2015 | 7 | 0.120 |
Why?
| Cluster Analysis | 1 | 2016 | 455 | 0.120 |
Why?
| Infant, Newborn | 4 | 2018 | 5048 | 0.120 |
Why?
| Neoplasm Proteins | 1 | 2018 | 385 | 0.120 |
Why?
| Schools | 1 | 2018 | 399 | 0.120 |
Why?
| Epithelial Cells | 2 | 2023 | 951 | 0.120 |
Why?
| Animals | 10 | 2021 | 31710 | 0.120 |
Why?
| Rural Health | 2 | 2006 | 67 | 0.120 |
Why?
| Parents | 2 | 2022 | 1186 | 0.120 |
Why?
| Infant, Premature | 1 | 2018 | 476 | 0.120 |
Why?
| Metabolic Diseases | 1 | 2015 | 98 | 0.120 |
Why?
| Antigens, Plant | 1 | 2014 | 47 | 0.120 |
Why?
| Dendritic Cells | 1 | 2017 | 435 | 0.120 |
Why?
| Physician-Patient Relations | 1 | 2018 | 462 | 0.110 |
Why?
| Specimen Handling | 1 | 2015 | 156 | 0.110 |
Why?
| Telemedicine | 1 | 2022 | 662 | 0.110 |
Why?
| Prognosis | 4 | 2017 | 3330 | 0.110 |
Why?
| Environmental Monitoring | 2 | 2013 | 254 | 0.110 |
Why?
| Respiratory Hypersensitivity | 1 | 2014 | 60 | 0.110 |
Why?
| Genetic Predisposition to Disease | 2 | 2021 | 2087 | 0.110 |
Why?
| Gene Expression | 1 | 2018 | 1421 | 0.110 |
Why?
| Hospitalization | 2 | 2021 | 1752 | 0.110 |
Why?
| Combined Modality Therapy | 1 | 2016 | 1121 | 0.110 |
Why?
| Leukotriene E4 | 2 | 2012 | 27 | 0.110 |
Why?
| Neutrophils | 2 | 2009 | 1176 | 0.110 |
Why?
| Research | 1 | 2016 | 394 | 0.110 |
Why?
| Biopsy | 2 | 2009 | 1036 | 0.100 |
Why?
| Indians, North American | 1 | 2018 | 570 | 0.100 |
Why?
| Obesity | 2 | 2018 | 2508 | 0.100 |
Why?
| Membrane Proteins | 1 | 2018 | 1019 | 0.100 |
Why?
| Homeostasis | 1 | 2015 | 573 | 0.100 |
Why?
| Decision Making | 1 | 2018 | 782 | 0.100 |
Why?
| Influenza, Human | 1 | 2017 | 545 | 0.100 |
Why?
| Predictive Value of Tests | 3 | 2017 | 1796 | 0.100 |
Why?
| Albuterol | 3 | 2012 | 102 | 0.100 |
Why?
| Adaptive Clinical Trials as Topic | 2 | 2021 | 19 | 0.100 |
Why?
| Case-Control Studies | 3 | 2019 | 3004 | 0.090 |
Why?
| Time Factors | 3 | 2016 | 6114 | 0.090 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 158 | 0.090 |
Why?
| Chronic Disease | 2 | 2009 | 1579 | 0.090 |
Why?
| Comorbidity | 2 | 2015 | 1448 | 0.090 |
Why?
| Genomics | 1 | 2015 | 635 | 0.090 |
Why?
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 32 | 0.090 |
Why?
| Physicians | 1 | 2018 | 772 | 0.090 |
Why?
| Logistic Models | 3 | 2010 | 1841 | 0.090 |
Why?
| Nedocromil | 1 | 2010 | 32 | 0.090 |
Why?
| Models, Statistical | 1 | 2013 | 599 | 0.080 |
Why?
| Vitamin D | 1 | 2013 | 341 | 0.080 |
Why?
| Health Personnel | 1 | 2015 | 574 | 0.080 |
Why?
| Budesonide | 1 | 2010 | 87 | 0.080 |
Why?
| Curriculum | 1 | 2015 | 819 | 0.080 |
Why?
| Hexosaminidases | 1 | 2009 | 17 | 0.080 |
Why?
| Immunoglobulin G | 4 | 2014 | 770 | 0.080 |
Why?
| Health Services Accessibility | 1 | 2015 | 763 | 0.080 |
Why?
| Immunoenzyme Techniques | 1 | 2009 | 192 | 0.080 |
Why?
| Food | 1 | 2010 | 160 | 0.080 |
Why?
| RNA | 1 | 2015 | 809 | 0.080 |
Why?
| Peroxidase | 1 | 2009 | 163 | 0.080 |
Why?
| Staining and Labeling | 1 | 2009 | 134 | 0.080 |
Why?
| DNA | 1 | 2015 | 1352 | 0.080 |
Why?
| Natural Killer T-Cells | 1 | 2009 | 63 | 0.080 |
Why?
| Exhalation | 3 | 2015 | 35 | 0.080 |
Why?
| Polysaccharides, Bacterial | 1 | 2008 | 66 | 0.080 |
Why?
| Glucocorticoids | 2 | 2011 | 532 | 0.070 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 916 | 0.070 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2009 | 470 | 0.070 |
Why?
| Prednisone | 1 | 2008 | 229 | 0.070 |
Why?
| Cohort Studies | 4 | 2018 | 4895 | 0.070 |
Why?
| Adrenergic beta-2 Receptor Agonists | 2 | 2018 | 32 | 0.070 |
Why?
| Macrophage Activation | 1 | 2008 | 164 | 0.070 |
Why?
| Gene Frequency | 2 | 2021 | 477 | 0.070 |
Why?
| Infant Care | 1 | 2007 | 42 | 0.070 |
Why?
| Community Health Nursing | 1 | 2007 | 57 | 0.070 |
Why?
| Tandem Mass Spectrometry | 1 | 2009 | 412 | 0.070 |
Why?
| Sequence Analysis, RNA | 2 | 2021 | 386 | 0.070 |
Why?
| C-Reactive Protein | 1 | 2009 | 362 | 0.070 |
Why?
| Patient Education as Topic | 1 | 2011 | 680 | 0.070 |
Why?
| Antigens, CD | 1 | 2009 | 442 | 0.070 |
Why?
| Manure | 1 | 2006 | 6 | 0.070 |
Why?
| Risk Assessment | 2 | 2006 | 2968 | 0.070 |
Why?
| Biomedical Research | 1 | 2012 | 585 | 0.070 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2018 | 1140 | 0.060 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2006 | 82 | 0.060 |
Why?
| India | 1 | 2006 | 134 | 0.060 |
Why?
| Maximum Tolerated Dose | 1 | 2006 | 183 | 0.060 |
Why?
| Electronics, Medical | 1 | 2005 | 8 | 0.060 |
Why?
| Research Design | 2 | 2021 | 928 | 0.060 |
Why?
| Environment | 1 | 2007 | 332 | 0.060 |
Why?
| Patient Compliance | 1 | 2009 | 525 | 0.060 |
Why?
| Bronchial Provocation Tests | 1 | 2005 | 51 | 0.060 |
Why?
| Interferon-alpha | 2 | 2017 | 186 | 0.060 |
Why?
| Macrophages | 2 | 2009 | 1263 | 0.060 |
Why?
| Salmeterol Xinafoate | 2 | 2018 | 41 | 0.060 |
Why?
| Exocrine Glands | 1 | 2004 | 4 | 0.060 |
Why?
| Basement Membrane | 1 | 2004 | 30 | 0.060 |
Why?
| Histamine H1 Antagonists | 1 | 2004 | 28 | 0.060 |
Why?
| Drug Administration Schedule | 1 | 2006 | 718 | 0.060 |
Why?
| Interleukin-13 | 2 | 2015 | 122 | 0.060 |
Why?
| Leukotrienes | 1 | 2004 | 35 | 0.060 |
Why?
| B-Lymphocytes | 1 | 2009 | 766 | 0.060 |
Why?
| Interleukin-12 Subunit p40 | 1 | 2003 | 7 | 0.060 |
Why?
| Cells, Cultured | 3 | 2018 | 3886 | 0.060 |
Why?
| Middle Aged | 6 | 2016 | 26740 | 0.050 |
Why?
| Administration, Sublingual | 2 | 2013 | 13 | 0.050 |
Why?
| Disease Outbreaks | 1 | 2006 | 307 | 0.050 |
Why?
| Cell Count | 1 | 2004 | 303 | 0.050 |
Why?
| Interleukin-12 | 1 | 2003 | 110 | 0.050 |
Why?
| Agriculture | 1 | 2003 | 72 | 0.050 |
Why?
| Cysteine | 1 | 2004 | 171 | 0.050 |
Why?
| Administration, Topical | 1 | 2003 | 138 | 0.050 |
Why?
| Bronchiolitis | 1 | 2004 | 81 | 0.050 |
Why?
| Breast Feeding | 1 | 2006 | 368 | 0.050 |
Why?
| Recurrence | 2 | 2018 | 935 | 0.050 |
Why?
| Protein Subunits | 1 | 2003 | 201 | 0.050 |
Why?
| Medicaid | 1 | 2006 | 407 | 0.050 |
Why?
| Lymphocytes | 1 | 2004 | 330 | 0.050 |
Why?
| Epithelium | 1 | 2023 | 295 | 0.050 |
Why?
| Interleukin-4 | 2 | 2015 | 206 | 0.050 |
Why?
| Practice Patterns, Physicians' | 1 | 2010 | 1177 | 0.050 |
Why?
| Inflammation | 3 | 2020 | 2480 | 0.050 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2021 | 59 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 1 | 2006 | 1842 | 0.050 |
Why?
| In Vitro Techniques | 1 | 2003 | 1016 | 0.050 |
Why?
| Disease Susceptibility | 1 | 2003 | 316 | 0.050 |
Why?
| Interleukin-10 | 1 | 2003 | 299 | 0.050 |
Why?
| Nasal Provocation Tests | 1 | 2021 | 3 | 0.050 |
Why?
| Th1 Cells | 1 | 2002 | 123 | 0.050 |
Why?
| T-Lymphocytes | 1 | 2009 | 1737 | 0.050 |
Why?
| Hydrocortisone | 1 | 2003 | 267 | 0.050 |
Why?
| Cytokines | 1 | 2008 | 1841 | 0.050 |
Why?
| Fungi | 1 | 2021 | 124 | 0.040 |
Why?
| Clinical Protocols | 1 | 2021 | 233 | 0.040 |
Why?
| Advisory Committees | 1 | 2021 | 208 | 0.040 |
Why?
| Breath Tests | 2 | 2012 | 82 | 0.040 |
Why?
| Immunotherapy | 1 | 2004 | 474 | 0.040 |
Why?
| Lymphocyte Activation | 1 | 2003 | 1037 | 0.040 |
Why?
| Anti-Inflammatory Agents | 1 | 2003 | 447 | 0.040 |
Why?
| A549 Cells | 1 | 2019 | 51 | 0.040 |
Why?
| Lipids | 1 | 2023 | 580 | 0.040 |
Why?
| Diagnosis, Differential | 1 | 2003 | 1342 | 0.040 |
Why?
| Common Cold | 1 | 2019 | 12 | 0.040 |
Why?
| Linear Models | 2 | 2013 | 768 | 0.040 |
Why?
| Tacrolimus Binding Proteins | 1 | 2018 | 16 | 0.040 |
Why?
| Vitamin D3 24-Hydroxylase | 1 | 2018 | 14 | 0.040 |
Why?
| Chicago | 1 | 2018 | 45 | 0.040 |
Why?
| Monitoring, Physiologic | 1 | 2020 | 249 | 0.040 |
Why?
| Analysis of Variance | 2 | 2015 | 1226 | 0.040 |
Why?
| Family | 1 | 2022 | 590 | 0.040 |
Why?
| Caregivers | 1 | 2005 | 717 | 0.040 |
Why?
| Retrospective Studies | 2 | 2015 | 12557 | 0.040 |
Why?
| Environmental Pollution | 1 | 2018 | 17 | 0.040 |
Why?
| Cell Death | 1 | 2019 | 323 | 0.040 |
Why?
| Maternal Health | 1 | 2018 | 42 | 0.040 |
Why?
| Interleukin-8 | 1 | 2018 | 237 | 0.040 |
Why?
| Morbidity | 1 | 2018 | 280 | 0.040 |
Why?
| Receptors, Glucocorticoid | 1 | 2018 | 130 | 0.030 |
Why?
| Vital Capacity | 1 | 2017 | 255 | 0.030 |
Why?
| Evidence-Based Practice | 1 | 2018 | 185 | 0.030 |
Why?
| Folic Acid | 1 | 2018 | 161 | 0.030 |
Why?
| Adrenergic beta-1 Receptor Agonists | 1 | 2016 | 5 | 0.030 |
Why?
| Metered Dose Inhalers | 1 | 2016 | 14 | 0.030 |
Why?
| Signal Transduction | 2 | 2020 | 4517 | 0.030 |
Why?
| Gene Expression Regulation, Viral | 1 | 2017 | 80 | 0.030 |
Why?
| Child Health | 1 | 2018 | 127 | 0.030 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2008 | 590 | 0.030 |
Why?
| Models, Biological | 1 | 2003 | 1621 | 0.030 |
Why?
| Bacteria | 1 | 2022 | 725 | 0.030 |
Why?
| Delayed-Action Preparations | 1 | 2016 | 159 | 0.030 |
Why?
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 5 | 0.030 |
Why?
| Patient Participation | 1 | 2018 | 358 | 0.030 |
Why?
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
| Respiratory Mucosa | 1 | 2017 | 251 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2016 | 6346 | 0.030 |
Why?
| Plant Proteins | 1 | 2014 | 81 | 0.030 |
Why?
| Medication Adherence | 1 | 2018 | 532 | 0.030 |
Why?
| Receptors, Immunologic | 1 | 2015 | 201 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 439 | 0.030 |
Why?
| Cross Reactions | 1 | 2014 | 118 | 0.030 |
Why?
| Community Health Services | 1 | 2015 | 212 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 1075 | 0.030 |
Why?
| Pregnancy | 2 | 2018 | 5520 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 355 | 0.030 |
Why?
| Th2 Cells | 1 | 2014 | 154 | 0.030 |
Why?
| Alleles | 1 | 2015 | 789 | 0.030 |
Why?
| Models, Genetic | 1 | 2015 | 562 | 0.030 |
Why?
| Patient Acceptance of Health Care | 1 | 2018 | 681 | 0.030 |
Why?
| Tomography, X-Ray Computed | 1 | 2021 | 2286 | 0.030 |
Why?
| Bronchi | 1 | 2014 | 232 | 0.030 |
Why?
| Eggs | 1 | 2012 | 30 | 0.030 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2018 | 452 | 0.030 |
Why?
| Mexican Americans | 1 | 2013 | 101 | 0.020 |
Why?
| Odds Ratio | 1 | 2014 | 953 | 0.020 |
Why?
| Milk | 1 | 2012 | 124 | 0.020 |
Why?
| Reproducibility of Results | 2 | 2009 | 2766 | 0.020 |
Why?
| Aged | 3 | 2016 | 19075 | 0.020 |
Why?
| Critical Care | 1 | 2015 | 476 | 0.020 |
Why?
| Evidence-Based Medicine | 1 | 2015 | 668 | 0.020 |
Why?
| Poverty Areas | 1 | 2011 | 32 | 0.020 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2017 | 959 | 0.020 |
Why?
| Quality Improvement | 1 | 2018 | 950 | 0.020 |
Why?
| Drug Utilization | 1 | 2012 | 167 | 0.020 |
Why?
| Sputum | 1 | 2012 | 286 | 0.020 |
Why?
| Administration, Oral | 1 | 2012 | 729 | 0.020 |
Why?
| Histamine Release | 1 | 2009 | 20 | 0.020 |
Why?
| Cyclopropanes | 1 | 2009 | 81 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2013 | 1430 | 0.020 |
Why?
| Cell Degranulation | 1 | 2009 | 39 | 0.020 |
Why?
| Risk | 1 | 2012 | 812 | 0.020 |
Why?
| Receptors, IgE | 1 | 2009 | 40 | 0.020 |
Why?
| Pilot Projects | 1 | 2013 | 1373 | 0.020 |
Why?
| Acetates | 1 | 2009 | 95 | 0.020 |
Why?
| Sulfides | 1 | 2009 | 94 | 0.020 |
Why?
| Quinolines | 1 | 2009 | 129 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2011 | 951 | 0.020 |
Why?
| Drug Resistance | 1 | 2008 | 158 | 0.020 |
Why?
| Sickness Impact Profile | 1 | 2007 | 50 | 0.020 |
Why?
| Health Surveys | 1 | 2009 | 443 | 0.020 |
Why?
| Dexamethasone | 1 | 2008 | 317 | 0.020 |
Why?
| Vulnerable Populations | 1 | 2007 | 134 | 0.020 |
Why?
| Respiratory Physiological Phenomena | 1 | 2006 | 29 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 740 | 0.020 |
Why?
| Growth | 1 | 2006 | 55 | 0.020 |
Why?
| Monocytes | 1 | 2008 | 504 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2009 | 1695 | 0.020 |
Why?
| Algorithms | 1 | 2012 | 1470 | 0.010 |
Why?
| Cats | 1 | 2005 | 193 | 0.010 |
Why?
| Disease-Free Survival | 1 | 2006 | 620 | 0.010 |
Why?
| Cotinine | 1 | 2005 | 69 | 0.010 |
Why?
| Dogs | 1 | 2005 | 334 | 0.010 |
Why?
| Regression Analysis | 1 | 2006 | 945 | 0.010 |
Why?
| Cell Line | 1 | 2009 | 2637 | 0.010 |
Why?
| Program Evaluation | 1 | 2007 | 822 | 0.010 |
Why?
| Home Care Services | 1 | 2005 | 223 | 0.010 |
Why?
| Body Mass Index | 1 | 2009 | 1959 | 0.010 |
Why?
| Rats | 1 | 2009 | 4959 | 0.010 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 1183 | 0.010 |
Why?
| Colorado | 1 | 2005 | 4100 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|